In a remarkable medical breakthrough, a 78-year-old man diagnosed with advanced lung cancer underwent successful treatment.

The safety profile for ORPATHYS ® plus TAGRISSO ® was consistent with the known profiles of each medicine, and there were no new safety findings. These data will be presented at a forthcoming medical ...

For decades, treatment relied largely on surgery, chemotherapy and radiation. While these therapies saved lives, advanced ...

A diagnosis of stage 4 lung cancer can immediately raise one of the most difficult questions for patients and their families: Is there still a chance of successful treatment? For many years, stage 4 ...

What Is Hyrnuo, and Why Does It Matter? Hyrnuo (sevabertinib) is a new oral medicine for adults with advanced nonsquamous non-small-cell lung cancer (NSCLC) carrying a specific genetic change known as ...

FirstHealth of the Carolinas’ Lung Cancer Program has again been named a Center of Excellence by GO2 for Lung Cancer, recognizing its patient-centered, evidence-based approach to lung ...

Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy determined ...

In his 20-year research career in Colorado, University of Colorado Cancer Center member D. Ross Camidge, MD, PhD, has published nearly 400 academic papers. But perhaps none have been so personal to ...

Alecensa reduced death risk by 22% compared to Xalkori in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. The study was not powered for OS, resulting in ...

LUNG transplant was associated with markedly longer early survival in selected patients with lung-limited stage IV NSCLC. The ...

When you’re living with extensive-stage small-cell lung cancer (ES-SCLC), your first treatment to slow the disease from worsening may be pretty different from your second. One key thing to know is ...

Julia Fontenot was 24 when she was diagnosed with metastatic synovial sarcoma. But she beat the odds, and managed to plan a ...